Possible prognostic role of IL-17R in osteosarcoma.
OBJECTIVE
An intense vascularization of primary tumor mass is associated with a fatal outcome in various types of invasive solid tumors. Interleukin 17 (IL-17), a CD4+ T-cell-derived cytokine, stimulates some tumor cells to secrete angiogenic factors, among which venous endothelial growth factor (VEGF). We assessed whether the expression of IL-17 receptor (IL-17R) represents a marker for the metastasizing ability of osteosarcoma (OS), a very malignant bone tumor.


METHODS
We immunoassayed the amount of VEGF secreted by three OS cell lines expressing IL-17R in differing amounts: HOS, MG63 and U-2 OS, and their sensitivity to IL-17 stimulation to secrete VEGF.


RESULTS
U-2 OS, which best expresses IL-17R, secreted the highest amounts of VEGF and was the most sensitive to IL-17, whereas MG63 expressed the lowest level of IL-17R, secreted the lowest amount of VEGF and was not sensitive to IL-17. IL-17R expression correlated with VEGF secretion and IL-17 sensitivity. U-2 OS expressed the most dedifferentiated phenotype, which is associated with tumor malignancy.


CONCLUSIONS
These results suggest that IL-17R in OS might represent a marker of tumor metastasis potential.
Honorati
Maria Cristina
MC
Dipartimento di Medicina Interna e Gastroenterologia, Università di Bologna, Via Massarenti 9, 40136 Bologna, Italy. labimge@alma.unibo.it
Cattini
Luca
L
Facchini
Andrea
A
D014408:Biomarkers, Tumor / Q000032:analysis; D001859:Bone Neoplasms / Q000378:metabolism* / Q000473:pathology*; D045744:Cell Line, Tumor; D006801:Humans; D009362:Neoplasm Metastasis; D012516:Osteosarcoma / Q000378:metabolism* / Q000473:pathology*; D011379:Prognosis; D053722:Receptors, Interleukin-17 / Q000378:metabolism*; D042442:Vascular Endothelial Growth Factors / Q000378:metabolism
D014408:Biomarkers, Tumor; D053722:Receptors, Interleukin-17; D042442:Vascular Endothelial Growth Factors
Br J Cancer. 2002 May 20;86(10):1566-77
12085206
J Bone Miner Res. 1996 Apr;11(4):512-20
8992882
Cell. 1996 Aug 9;86(3):353-64
8756718
Pediatr Hematol Oncol. 2004 Oct-Nov;21(7):611-9
15626017
Clin Exp Immunol. 2003 Sep;133(3):344-9
12930359
Mod Pathol. 2006 May;19(5):738-45
16528367
J Natl Cancer Inst. 2006 Mar 1;98(5):316-25
16507828
J Immunol. 2005 Nov 1;175(9):6177-89
16237115
Cancer. 2007 Mar 1;109(5):813-9
17265525
Clin Cancer Res. 2000 Feb;6(2):572-7
10690541
Cell. 2000 Jan 7;100(1):57-70
10647931
Semin Cell Dev Biol. 2005 Aug-Oct;16(4-5):554-63
16144692
Osteoarthritis Cartilage. 2006 Apr;14(4):345-52
16311048
Mol Divers. 2006 Nov;10(4):515-27
16972015
Anticancer Res. 2003 May-Jun;23(3A):1969-96
12894571
Cancer Res. 1999 Dec 1;59(23):6010-4
10606250
Blood. 2003 Apr 1;101(7):2620-7
12411307
Osteoarthritis Cartilage. 2004 Sep;12(9):683-91
15325633
J Egypt Natl Canc Inst. 2004 Mar;16(1):57-61
15716999
Bone. 1994 Nov-Dec;15(6):585-91
7873286
Nature. 2004 Feb 26;427(6977):787
14985739
J Bone Miner Res. 2000 Jul;15(7):1257-65
10893674
Biochem Biophys Res Commun. 2001 Apr 6;282(3):735-8
11401524
Cancer. 2006 Jun 15;106(12):2682-91
16691621
Oncol Rep. 2006 Jul;16(1):17-23
16786118
Eur J Intern Med. 2006 Oct;17(6):412-6
16962948
Ann Surg. 2003 Jul;238(1):9-28
12832961
FASEB J. 2002 Sep;16(11):1361-70
12205027
Int J Oncol. 1993 Nov;3(5):963-9
21573460
Int Semin Surg Oncol. 2006 Mar 21;3:7
16551370